Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries

Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between baseline factors and discontinuation of bisphosphonate therapy at 12 months of follow-up based on discontinuation definition I during the period 2006–2009, cohort analyses

				Discontinuation definition I^a
Patient baseline characteristics				Adjusted^bOR (95% CI)
Sex	Male	vs	Female	1.1 (1.0-1.2)*
Race	Black	vs	White	1.1 (0.9-1.2)
	Asian	vs	White	0.9 (0.8-1.0)
	Hispanic	vs	White	1.1 (1.0-1.3)*
	Other	vs	White	1.0 (0.9-1.2)
Age	70-74	vs	65-69	1.0 (0.9-1.1)
	75-79	vs	65-69	1.0 (0.9-1.1)
	80-84	vs	65-69	1.0 (0.9-1.1)
	85plus	vs	65-69	1.0 (0.9-1.1)
Region	Midwest	vs	Northeast	0.9 (0.8-1.0)
	South	vs	Northeast	1.1 (1.0-1.2)*
	West	vs	Northeast	1.0 (0.9-1.1)
Area income 45000	30000-	vs	< 30000	0.9 (0.8-1.0)
60000	45000-	vs	< 30000	0.9 (0.8-0.9)*
75000	60000-	vs	< 30000	0.9 (0.8-0.9)*
	75000+	vs	< 30000	0.8 (0.8-0.9)*
Charlson score	1-2	vs	0	1.0 (0.9-1.1)
	> 2	vs	0	1.1 (1.0-1.2)*
Number of physician visits	6-10	vs	0-5	1.1 (1.0-1.2)
	11-15	vs	0-5	1.1 (1.0-1.2)*
	> 15	vs	0-5	1.3 (1.1-1.4)*
Hospitalization at baseline				1.0 (1.0-1.1)
Long-term care stay at baseline				0.6 (0.5-0.7)*
Fracture at baseline				0.9 (0.8-1.0)*
Dual-energy X-ray absorptiometry at baseline				0.8 (0.8-0.9)*
Internal medicine physician visit at baseline				1.0 (0.9-1.0)
Family practice physician visit at baseline				1.0 (0.9-1.1)
Oncologist visit at baseline				0.9 (0.8-1.0)*
Rheumatologist or endocrinologist visit at baseline				0.8 (0.7-0.9)*
Osteoporosis				0.8 (0.8-0.9)*
Proton pump inhibitors				0.8 (0.7-1.0)*

^aDiscontinuation definition I: Totally discontinued all anti-osteoporosis drugs as of the end of follow up.
^bAdjusted for all factors listed in the table, and urban/rural residency, entering Medicare part D coverage gap at baseline, glucocorticoid-related and fall-related (predisposing to falls) conditions, diabetes, chronic kidney disease, depressive illness, acute myocardial infarction, other heart disease, metabolic bone disease, cancer, anticonvulsants, antidepressants, antipsychotics, antihypertensives, lipid-lowering drugs, non-steroidal anti-inflammatory drugs, steroids, H2-receptor blockers, hormone replacement therapy, thiazolidinediones, and aromatase inhibitors.
*p < =0.05.

ISSN: 1471-2474